Amarin Corp Plc (AMRN)

[Jasbg]

Stockboy,

https://en.wikipedia.org/wiki/Ethyl_eicosapentaenoic_acid

Ethyl eicosapentaenoic acid (E-EPA, icosapent ethyl), sold under the brand name Vascepa among others, is a medication used to treat dyslipidemia[4] and hypertriglyceridemia.[3] It is used in combination with changes in diet in adults with hypertriglyceridemia = 150 mg/dL. Further, it is often required to be used with a statin (maximally-tolerated dose).[6]

It is made from the omega-3 fatty acid eicosapentaenoic acid (EPA).[6] The US Food and Drug Administration (FDA) granted the approval of icosapent ethyl in 2012 to Amarin Corporation, and it became the second fish oil-based medication after omega-3-acid ethyl esters (brand named Lovaza, itself approved in 2004).[7] On 13 December 2019, the FDA also approved Vascepa as the first drug specifically "to reduce cardiovascular risk among people with elevated triglyceride levels".[6] It is available as a generic medication.[8] In 2020, it was the 285th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[9][10]